Medical experts came together to address matters concerning the different types of headaches commonly experienced today.

Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer. Merck and Eisai on Friday ...

AUSTIN (KXAN)– The Hi How Are You Project has been teaching students how to be aware and manage their mental health for seven years. This month the project celebrates Austin’s Hi How Are You ...

The constraint has been a lack of good drugs to treat those patients. Eisai and Biogen, with Leqembi, and Eli Lilly, with Kisunla, have begun the process of establishing a drug arsenal for ...

Which is what we have done for this issue of What Hi-Fi?. In February's magazine you will find five brilliant stereo systems based on Award-winning kit. It is always tempting to put “Award-winning ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) accepted a marketing application for an injectable version of their Alzheimer ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly ...

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

On Monday, the FDA accepted Eisai Co., Ltd. (OTC:ESALY) and Biogen Inc’s (NASDAQ:BIIB) Biologics License Application (BLA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector (SC-AI ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Since the release of OpenAI’s ChatGPT, generative AI tools have been helping us answer questions, write ...

NEW YORK – The US Food and Drug Administration has accepted Eisai's biologics license application (BLA) seeking approval for a subcutaneous form of Leqembi (lecanemab) that can be dosed as maintenance ...